DIHEXA
Click Here To Complete
Health Questionnaire
We Will Contact You To Complete The Evaluation Process
DIHEXA is a peptide variant derived from angiotensin IV. Clinical studies suggest that DIHEXA improves cognitive function as shown in animal models of disease such as Alzheimerās. Angiotensin IV is a derivative of the vasoconstrictor angiotensin II which has been shown in animal studies to enhance acquisition, consolidation and recall of learning and memory when administered centrally or peripherally. In an assay of neurotrophic activity, DIHEXA was found to be seven orders of magnitude more potent than brain-derived neurotrophic factor and is thought may be able to help in the repair of the brain and nerves in neurological disease.
*The purchase of this product is for an individualized consultation that requires a 15 minute telemedicine visit and establishment as a patient in our practice. At that time an individualized treatment plan will be initiated with appropriate therapy based on your medical history and health assessment. Our peptides are compounded only at fully accredited and licensed US Pharmacies and we only ship to within the US. Due to individual State Pharmacy laws, not all peptides are available in all states. Not all peptides are FDA approved and many are prescribed for off label use at the discretion of the prescribing provider. Because not all peptides are always available and my require compounding, please allow 5-10 business days for delivery even though most peptides will arrive within 3-4 business days of telemedicine consult.
Click Here To Complete
Health Questionnaire
We Will Contact You To Complete The Evaluation Process
A subset of angiotensin IV (AngIV)ārelated molecules are known to possess procognitive/antidementia properties and have been considered as templates for potential therapeutics. However, this potential has not been realized because of two factors: 1) a lack of blood-brain barrierāpenetrant analogs, and 2) the absence of a validated mechanism of action. The pharmacokinetic barrier has recently been overcome with the synthesis of the orally active, blood-brain barrierāpermeable analog N-hexanoic-tyrosine-isoleucine-( 6) aminohexanoic amide (dihexa). Therefore, the goal of this study was to elucidate the mechanism that underlies dihexaās procognitive activity. Here, we demonstrate that dihexa binds with high affinity to hepatocyte growth factor (HGF) and both dihexa and its parent compound Norleucine 1-AngIV (Nle1-AngIV) induce c-Met phosphorylation in the presence of subthreshold concentrations of HGF and augment HGF-dependent cell scattering. Further, dihexa and Nle1-AngIV induce hippocampal spinogenesis and synaptogenesis similar to HGF itself. These actions were inhibited by an HGF antagonist and a short hairpin RNA directed at c-Met. Most importantly, the procognitive/antidementia capacity of orally delivered dihexa was blocked by an HGF antagonist delivered intracerebroventricularly as measured using the Morris water maze task of spatial learning.Ā
